Last reviewed · How we verify
NCT05238181: PM_in_AIG
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
trial testing Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains in Autoimmune Diseases in 300 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | National Cheng-Kung University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Assess pyloric or pseudopyloric metaplasia of corpus by H&E stains
- Assess pyloric or pseudopyloric metaplasia of corpus by TFF2 immunohistochemistry stains
- The assessment of corpus-predominant gastritis index (CGI), Operative Link for Gastritis Assessment (OLGA), and Operative Link on Gastric Intestinal Metaplasia assessment (OLGIM)
Conditions studied
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
- Helicobacter Pylori Gastritis — all drugs for Helicobacter Pylori Gastritis →
- Anemia, Pernicious — all drugs for Anemia, Pernicious →
- Metaplasia — all drugs for Metaplasia →
Sponsor
National Cheng-Kung University Hospital
Who can join
Adults 20 to 90, any sex, with Autoimmune Diseases or Helicobacter Pylori Gastritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is aimed to investigate the different rates of pyloric/ pseudopyloric metaplasia or spasmolytic polypeptide-expressing metaplasia (SPEM) of corpus between autoimmune gastritis and H. pylori-infected non-ulcer dyspepsia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05238181
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autoimmune Diseases
Currently open trials in the same condition.
- NCT06948110 — Deciphering the Genetic Architecture of Autoimmune Diseases · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07408336 — Clinical Study of AFN50 Injection in the Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT07283315 — Exploratory Clinical Study of Second-generation CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in Treating Paedia · EARLY_PHASE1 · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
Other National Cheng-Kung University Hospital trials
Trials by the same sponsor.
- NCT07525713 — Virtual Reality Mirror Therapy With Focused Object-Directed Attention System · NA · not yet recruiting
- NCT07369271 — Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery · NA · not yet recruiting
- NCT07262411 — Peer-based Recovery Program · NA · not yet recruiting
- NCT07257926 — Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Contr · Phase 4 · not yet recruiting
- NCT07269132 — Applying the ADDIE Model to Develop a Multimedia Program to Enhance Chemotherapy Knowledge and Self-Efficacy Among Inten · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05238181 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cheng-Kung University Hospital
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05238181.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing